Write for the people who write drug policy.
The Drug Report publishes editorials, commentary and analysis from scientists, clinicians, former officials, parents, people in recovery and advocates. Our readers are the lawmakers, staff, officials, researchers and reporters who shape drug policy. If you have something to say to them, we want to hear it.
- Op-eds and editorials that make a clear argument about an issue in the news: marijuana, hemp THC, kratom, fentanyl, psychedelics, alcohol, tobacco, or the industries behind them.
- Commentary on new research. What a study found, what it missed, and why it matters for policy.
- Responses to something we published or something in the news.
- First-person accounts from parents, patients, people in recovery, clinicians and law enforcement.
- Letters to the editor of 250 words or fewer.
- Length. Op-eds and commentary run 600 to 1,200 words. Letters run up to 250.
- Exclusivity. Submissions must be original and exclusive to The Drug Report. We do not run pieces that have appeared elsewhere, including on personal blogs or social media.
- Sourcing. Link to studies, data and documents you cite. We fact-check before publication.
- Author information. Include your full name, title and affiliation, a one-line bio, and a phone number in case our editors have questions. We do not publish anonymous pieces.
- Editing. We edit for length, clarity and style, and we will clear substantive changes with you before publication.
- Independence. We do not accept submissions written or funded by the marijuana, hemp THC, kratom or psychedelics industries.
What happens next. Our editors read every submission. If we plan to run your piece, you will hear from us within five business days. If you have not heard back in that time, you are free to submit it elsewhere.
Have an idea but not a draft yet? Send us a short pitch, two or three sentences, and we will tell you whether it is a fit before you write it.
Submissions and questions: [email protected] · News tips and corrections: [email protected] · Media and interview requests: [email protected]
